Kalvista Drug Patent Portfolio
Kalvista owns 1 orange book drug protected by 8 US patents Given below is the list of Kalvista's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11234939 | Dosage Forms Comprising A Plasma Kallikrein Inhibitor | 26 Jan, 2039 | Active |
| US11230537 | Polymorphs Of N-[(3-Fluoro-4-Methoxypyridin-2-Yl)Methyl]-3-(Methoxymethyl)-1-({4-[2-Oxopyridin-1-Yl)Methyl]Phenyl} Methyl)Pyrazole-4-Carboxamide As Iallikrein Inhibitors | 25 Dec, 2037 | Active |
| US11739068 | Polymorphs Of N-[(3-Fluoro-4-Methoxypyridin-2-Yl)Methyl]-3-(Methoxymethyl)-1-({4-[(2-Oxopyridin-1-Yl)Methyl]Phenyl}Methyl)Pyrazole-4-Carboxamide And Salts Thereof | 23 Jun, 2037 | Active |
| US10364238 | N-((Het) Arylmethyl)-Heteroaryl-Carboxamides Compounds As Plasma Kallikrein Inhibitors | 26 Nov, 2035 | Active |
| US10611758 | N-((Het)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | 26 Nov, 2035 | Active |
| US11001578 | N-((Het)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Plasma Kallikrein Inhibitors | 26 Nov, 2035 | Active |
| US11084809 | N-((Het)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | 26 Nov, 2035 | Active |
| US11198691 | N-((Het)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors | 26 Nov, 2035 | Active |
Latest Legal Activities on Kalvista's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Kalvista.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Initial letter Re: PTE Application to regulating agency | 22 Aug, 2025 | US11230537 |
| Initial letter Re: PTE Application to regulating agency | 22 Aug, 2025 | US11198691 |
| Initial letter Re: PTE Application to regulating agency | 22 Aug, 2025 | US11084809 |
| Initial letter Re: PTE Application to regulating agency | 22 Aug, 2025 | US11234939 |
| Initial letter Re: PTE Application to regulating agency | 22 Aug, 2025 | US10364238 |
| Initial letter Re: PTE Application to regulating agency | 22 Aug, 2025 | US10611758 |
| Initial letter Re: PTE Application to regulating agency | 22 Aug, 2025 | US11739068 |
| Initial letter Re: PTE Application to regulating agency | 22 Aug, 2025 | US11001578 |
| Patent Term Extension Application under 35 USC 156 Filed | 21 Aug, 2025 | US11001578 |
| Patent Term Extension Application under 35 USC 156 Filed | 21 Aug, 2025 | US11230537 |
| Patent Term Extension Application under 35 USC 156 Filed | 20 Aug, 2025 | US11084809 |
| Patent Term Extension Application under 35 USC 156 Filed | 20 Aug, 2025 | US10364238 |
| Patent Term Extension Application under 35 USC 156 Filed | 20 Aug, 2025 | US11739068 |
| Patent Term Extension Application under 35 USC 156 Filed | 20 Aug, 2025 | US11198691 |
| Patent Term Extension Application under 35 USC 156 Filed | 20 Aug, 2025 | US10611758 |
Kalvista's Family Patents
Kalvista Drug List
Given below is the complete list of Kalvista's drugs and the patents protecting them.
1. Ekterly
Ekterly is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11234939 | Dosage Forms Comprising A Plasma Kallikrein Inhibitor |
26 Jan, 2039
(12 years from now)
| Active |
| US11230537 | Polymorphs Of N-[(3-Fluoro-4-Methoxypyridin-2-Yl)Methyl]-3-(Methoxymethyl)-1-({4-[2-Oxopyridin-1-Yl)Methyl]Phenyl} Methyl)Pyrazole-4-Carboxamide As Iallikrein Inhibitors |
25 Dec, 2037
(11 years from now)
| Active |
| US11739068 | Polymorphs Of N-[(3-Fluoro-4-Methoxypyridin-2-Yl)Methyl]-3-(Methoxymethyl)-1-({4-[(2-Oxopyridin-1-Yl)Methyl]Phenyl}Methyl)Pyrazole-4-Carboxamide And Salts Thereof |
23 Jun, 2037
(11 years from now)
| Active |
| US10364238 | N-((Het) Arylmethyl)-Heteroaryl-Carboxamides Compounds As Plasma Kallikrein Inhibitors |
26 Nov, 2035
(9 years from now)
| Active |
| US10611758 | N-((Het)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors |
26 Nov, 2035
(9 years from now)
| Active |
| US11001578 | N-((Het)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Plasma Kallikrein Inhibitors |
26 Nov, 2035
(9 years from now)
| Active |
| US11084809 | N-((Het)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors |
26 Nov, 2035
(9 years from now)
| Active |
| US11198691 | N-((Het)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein Inhibitors |
26 Nov, 2035
(9 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ekterly's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List